What is the difference between Edluar and Ambien for treating insomnia? Explore the key facts, reviews, and comparisons in this comprehensive article.

The Battle of the Insomnia Treatments: Edluar vs Ambien

Insomnia is a prevalent sleep disorder that affects millions of individuals worldwide, and the search for effective treatments has led to the development of various pharmaceutical options. Two of the prominent contenders in the insomnia treatment landscape are Edluar and Ambien, both of which have garnered significant attention from healthcare professionals and patients alike.

Edluar: A Sublingual Zolpidem Solution

Edluar is a sublingual formulation of the active ingredient zolpidem, a widely-used sedative-hypnotic medication. Zolpidem has been demonstrated to effectively facilitate the onset and maintenance of sleep, making it a popular choice for the management of insomnia. The sublingual administration of Edluar allows for a more rapid absorption of the active ingredient, potentially leading to quicker sleep onset compared to the traditional oral formulation.

According to reviews on Drugs.com, Edluar has an impressive average rating of 9.2 out of 10 from a total of 12 reviews for the treatment of insomnia. An overwhelming 92% of reviewers reported a positive experience, while 0% reported a negative experience. This high level of patient satisfaction suggests that Edluar may be an effective and well-tolerated option for those struggling with insomnia.

Ambien: The Oral Zolpidem Alternative

Ambien, the brand name for the oral formulation of zolpidem, is another widely-recognized medication for the treatment of insomnia. Like Edluar, Ambien has been shown to facilitate the onset and maintenance of sleep, making it a popular choice among healthcare providers and patients.

Comparing Edluar and Ambien: Key Differences

While both Edluar and Ambien contain the same active ingredient, zolpidem, there are some key differences between the two formulations. The primary distinction lies in the route of administration, with Edluar being a sublingual formulation and Ambien being an oral tablet.

The sublingual administration of Edluar allows for a more rapid absorption of the active ingredient, potentially leading to a quicker onset of sleep compared to the oral formulation of Ambien. This faster absorption may be particularly beneficial for individuals who struggle with falling asleep quickly.

Another notable difference is the bioavailability of the two formulations. Sublingual administration, as seen with Edluar, generally results in a higher bioavailability of the active ingredient compared to oral administration, as the drug is absorbed directly into the bloodstream through the mucous membranes of the mouth.

Efficacy and Safety Profiles: Edluar vs Ambien

Both Edluar and Ambien have been extensively studied for their efficacy and safety in the treatment of insomnia. A randomized, double-blind, crossover study published in Current Medical Research and Opinion in 2010 compared the hypnotic effects of a single dose of sublingual zolpidem (Edluar) and oral zolpidem (Ambien) in patients with primary insomnia.

The study found that sublingual zolpidem (Edluar) significantly shortened the latency to persistent sleep (LPS) by 34% or 10.3 minutes compared to oral zolpidem (Ambien). Additionally, sublingual zolpidem was associated with a faster onset of sleep, as measured by sleep onset latency (SOL) and latency to stage 1 (ST1L).

In terms of safety, both Edluar and Ambien are generally well-tolerated, with the most common side effects being drowsiness, dizziness, and headache. It is important to note that both medications should be used with caution, as they can be potentially addictive and should not be used for extended periods without medical supervision.

Choosing Between Edluar and Ambien: Factors to Consider

When it comes to choosing between Edluar and Ambien for the treatment of insomnia, several factors should be taken into account. Factors such as the individual’s response to the medications, personal preferences, and the guidance of a healthcare professional should all be considered.

Patients who prioritize a faster onset of sleep may find Edluar’s sublingual formulation more appealing, as the quicker absorption of the active ingredient can lead to a quicker sleep induction. On the other hand, individuals who prefer the traditional oral administration or have concerns about the potential for higher bioavailability with the sublingual route may opt for Ambien.

Ultimately, the decision should be made in consultation with a healthcare provider, who can assess the individual’s medical history, sleep patterns, and any other relevant factors to determine the most appropriate treatment option.

Conclusion

In the battle of the insomnia treatments, both Edluar and Ambien have their strengths and weaknesses. Edluar’s sublingual formulation may offer a faster onset of sleep, while Ambien’s oral administration may be preferred by those with specific concerns. Ultimately, the choice between the two should be made in close collaboration with a healthcare professional to ensure the most effective and personalized treatment plan for each individual’s insomnia needs.

Edluar for Insomnia Reviews – Drugs.com

Print

Save

Edluar
has an average rating of 9.2 out of 10 from a total of 12 reviews
for the
treatment of Insomnia.
92% of reviewers reported a positive experience, while 0% reported a negative experience.

Edluar rating summary

9.2/10 average rating

12 ratings from 13 user reviews.

Compare all 83 medications used in the treatment of Insomnia.

Reviews for Edluar

Frequently asked questions

• Quviviq vs. Ambien: How do they compare?
• Ambien: What are 11 Things You Need to Know?
• Why am I unable to sleep after taking Ambien?
• Is Ambien safe for long-term use?

Are you taking this medicine?

• Add your review
• Learn more about Edluar

More FAQ

• Is Ambien a benzo?
• Is Ambien addictive?
• What is this pill? Tannish peach color, elliptical, marked 10 MG and 5 dots in a small box?
• What is the half life of Ambien?

Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.

Learn more about Insomnia

• Anticholinergic Drugs to Avoid in the Elderly
• Benzodiazepines: Overview and Use
• Sleep (Insomnia) Medications and Alcohol Interactions

Care guides

• Insomnia

Symptoms and treatments

• Insomnia

Medicine.

com guides (external)

• Insomnia Guide

More about Edluar (zolpidem)

• Check interactions
• Compare alternatives
• Pricing & coupons
• Drug images
• Latest FDA alerts (4)
• Side effects
• Dosage information
• During pregnancy
• Generic availability
• FDA approval history
• Drug class: miscellaneous anxiolytics, sedatives and hypnotics
• Breastfeeding
• En español

Patient resources

• Drug Information

Other brands

Ambien, Ambien CR, Zolpimist, Intermezzo

Professional resources

• Prescribing Information

Related treatment guides

• Insomnia

Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia

Randomized Controlled Trial

. 2010 Jun;26(6):1423-31.

doi: 10. 1185/03007991003788225.

Corinne Staner 
¹
, Frédéric Joly, Nathalie Jacquot, Irina D Vlasova, Maria Nehlin, Thomas Lundqvist, Charlotte Edenius, Luc Staner

Affiliations

Affiliation

• ¹ Forenap Pharma, Rouffach, France.

• PMID:

  20397964

• DOI:

  10.1185/03007991003788225

Randomized Controlled Trial

Corinne Staner et al.

Curr Med Res Opin.

2010 Jun.

. 2010 Jun;26(6):1423-31.

doi: 10.1185/03007991003788225.

Authors

Corinne Staner 
¹
, Frédéric Joly, Nathalie Jacquot, Irina D Vlasova, Maria Nehlin, Thomas Lundqvist, Charlotte Edenius, Luc Staner

Affiliation

• ¹ Forenap Pharma, Rouffach, France.

• PMID:

  20397964

• DOI:

  10.1185/03007991003788225

Abstract

Objective:

To compare the hypnotic effects of a single dose of a sublingual formulation of zolpidem (Edluar*) 10 mg vs oral formulation (Ambien dagger ) 10 mg by polysomnography (PSG) in DSM-IV primary insomnia patients. Primary objective was to compare the two formulations on sleep induction, measured by latency to persistent sleep (LPS), sleep onset latency (SOL) and latency to stage 1 (ST1L).

Research and methods:

This was a randomized, double-blind, two-period, cross-over multi-centre study in which each period comprised two successive PSG recording nights. Treatment was administered when PSG recordings started. Subjective sleep and residual effects were assessed the next morning.

Results:

Seventy female and male patients aged 19-64 were analysed. Sublingual zolpidem significantly shortened LPS by 34% or 10.3 minutes as compared to oral zolpidem (95% CI: -4.3 min to -16.2 min, p = 0.001). SOL and ST1L were also significantly shortened (p < 0.01). Furthermore the two formulations were comparable in terms of sleep maintenance properties based on total sleep time (TST). The improvement in subjective sleep and next-day residual effects did not differ between the two treatments. Both routes of administration were well tolerated.

Conclusions:

The results demonstrate that sublingual zolpidem is superior to an equivalent dose of oral zolpidem in terms of sleep inducing properties in a carefully selected sample of primary insomnia patients.

Similar articles

• Sublingual zolpidem (Edluar™; Sublinox™).

  Yang LP, Deeks ED.

  Yang LP, et al.
  CNS Drugs. 2012 Nov;26(11):1003-10. doi: 10.1007/s40263-012-0009-y.
  CNS Drugs. 2012.

  PMID: 23034583

  Review.

• Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep in the post-nap model of transient insomnia: a polysomnographic study.

  Staner L, Eriksson M, Cornette F, Santoro F, Muscat N, Luthinger R, Roth T.

  Staner L, et al.
  Sleep Med. 2009 Jun;10(6):616-20. doi: 10.1016/j.sleep.2008.06.008. Epub 2008 Nov 8.
  Sleep Med. 2009.

  PMID: 18996742

  Clinical Trial.

• Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.

  Roth T, Soubrane C, Titeux L, Walsh JK; Zoladult Study Group.

  Roth T, et al.
  Sleep Med. 2006 Aug;7(5):397-406. doi: 10.1016/j.sleep.2006.04.008. Epub 2006 Jul 3.
  Sleep Med. 2006.

  PMID: 16815744

  Clinical Trial.

• Lower doses of sublingual Zolpidem are more effective than oral Zolpidem to anticipate sleep onset in healthy volunteers.

  Valente KD, Hasan R, Tavares SM, Gattaz WF.

  Valente KD, et al.
  Sleep Med. 2013 Jan;14(1):20-3. doi: 10.1016/j.sleep.2012.09.003. Epub 2012 Dec 4.
  Sleep Med. 2013.

  PMID: 23218533

  Clinical Trial.

• A new sublingual formulation of zolpidem for the treatment of sleep-onset insomnia.

  Staner L, Danjou P, Luthringer R.

  Staner L, et al.
  Expert Rev Neurother. 2012 Feb;12(2):141-53. doi: 10.1586/ern.11.197.
  Expert Rev Neurother. 2012.

  PMID: 22288669

  Review.

See all similar articles

Cited by

• Sublingual and oral zolpidem for insomnia disorder: a 3-month randomized trial.

  Castro LS, Otuyama LJ, Fumo-Dos-Santos C, Tufik S, Poyares D.

  Castro LS, et al.
  Braz J Psychiatry. 2020 Apr;42(2):175-184. doi: 10.1590/1516-4446-2019-0389. Epub 2019 Dec 20.
  Braz J Psychiatry. 2020.

  PMID: 31859791
  Free PMC article.

  Clinical Trial.

• Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.

  Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL.

  Sateia MJ, et al.